Eli Lilly and Co
(BSP:LILY34)
R$
154
-1.68 (-1.08%)
Market Cap: 4.43 Tn
Enterprise Value: 4.59 Tn
PE Ratio: 86.21
PB Ratio: 50.39
GF Score: 77/100 
Eli Lilly and Co at UBS Global Healthcare Conference (Virtual) Transcript
May 19, 2020 / 02:50PM GMT
Release Date Price:
R$29.83
(-2.28%)
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Hello, and welcome to day 2 of the UBS Global Healthcare Conference. My name is Navin Jacob. I'm the senior analyst covering large tech pharmaceuticals and smid-cap biotech. Our next presentation or fireside chat is with Eli Lilly. It's my pleasure to have with us Mike Mason, President of Lilly Diabetes, as well as Mike Czapar from the Investor Relations team. Mike and Mike, thank you so much for joining us today. Hope you're both well.
Michael B. Mason
Eli Lilly and Company - Senior VP & President of Lilly Diabetes
Thank you. Yes, we're both healthy and safe.
Questions & Answers
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Fantastic. That's great to hear. And so why don't we start at a broad level with a topic that can't be escaped, obviously COVID-19. We'll start
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers